Literature DB >> 1738171

Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer.

M A Eisenberger, J A Fontana.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1738171     DOI: 10.1093/jnci/84.1.3

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  3 in total

Review 1.  Current concepts of treatment in medical oncology: new anticancer drugs.

Authors:  C Unger
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro.

Authors:  J A Foekens; A M Sieuwerts; E M Stuurman-Smeets; H A Peters; J G Klijn
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

Review 3.  Suramin's development: what did we learn?

Authors:  Maninderjeet Kaur; Eddie Reed; Oliver Sartor; William Dahut; William D Figg
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.651

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.